TROCULEUCEL
Cell therapy targets TGFBR2 via inhibition
Trials 75 · started per year
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07443020 Background | May 2026 → Mar 2033 expected | malignant mesothelioma, pleural neoplasm | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Recruiting | No outcome recorded |
| Phase 1 | NCT06190249 Background | Dec 2024 → Jan 2028 | melanoma | James Isaacs, MD | Withdrawn | No outcome recorded |
| Phase 1 | NCT02118285 Background | Jul 2014 → Nov 2015 | fallopian tube carcinoma, ovarian cancer, primary peritoneal carcinoma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00059475 Background | Apr 2003 → May 2010 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-04-21 | Kite, A Gilead Company | Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies Focused on Natural Killer (NK) Cells kitepharma.com ↗ |
| 2020-04-21 | Gilead Sciences | Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies Focused on Natural Killer (NK) Cells gilead.com ↗ |
Evidence & citations 23 cited values
Every value below carries the sentence it was read from. 81 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TROCULEUCEL | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314888 ↗ |
| Known as | Adoptive Cellular Therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01077908 ↗ |
| Known as | Adoptive Immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02757391 ↗ |
| Known as | Allogeneic natural killer cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00652899 ↗ |
| Known as | Allogenic NK cells | “Allogenic NK cells will then be adoptively transferred by hepatic intraarterial infusion according to a dose escalation protocol” NCT02845999 ↗ |
| Known as | Autologous natural killer cells | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314888 ↗ |
| Known as | CD3-CD56+ natural killer cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01639456 ↗ |
| Known as | Cytokine Induced Memory-like Natural Killer (CIML NK) Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06318871 ↗ |
| Known as | IL-2 NK | “prophylactic donor-derived ex vivo IL-2 activated NK cell (IL-2 NK) infusion after allo-HSCT for patients with hematologic malignancies.” PMID 34071607 ↗ May 2021 |
| Known as | Interleukin-2 (IL-2) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07443020 ↗ |
| Known as | natural killer (NK) cells | “We therefore propose this non-randomized, Phase I, dose escalating study designed to evaluate the safety and the anti- tumor effects of escalating doses of adoptively infused...” NCT00720785 ↗5“received highly purified CD56(+)CD3(-) natural killer (NK) cells from haploidentical killer immunoglobulin-like receptor-ligand mismatched donors” PMID 21791425 ↗ Jul 2011 “We are trying to achieve a similar result using a less complex and less costly approach, with Natural Killer (NK) cells.” NCT00717184 ↗ “The infusion of natural killer (NK) cells will be performed in the Infusion Center at New England Medical Center.” NCT00660166 ↗ “the combined therapy using cryosurgery and natural killer (NK) cells” NCT02849366 ↗ “Natural Killer (NK) Cells” NCT03242603 ↗ |
| Known as | Natural Killer (NK) Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00328861 ↗ |
| Known as | natural killer cell (NK) therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00354172 ↗ |
| Known as | Natural killer cells | “Natural killer cells are blood cells that are responsible for eliminating cancer cells especially when there are only a few.” NCT00660166 ↗14“infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia” NCT04578210 ↗ “Natural killer cells (NK cells) have MHC-unrestricted killing effect on malignant tumor cells” NCT02399735 ↗ “Natural killer cells (NK cells) are derived from bone marrow lymphoid stem cells” NCT05143125 ↗ |
| Known as | nature killer(NK) cells | “The pancreatic cancer patients will receive nature killer(NK) cells infusions,qd” NCT02718859 ↗ |
| Known as | NK cells | “This study aims to test whether haploidentical NK cells from healthy individuals, expanded and activated in vitro, administered when the disease is nearly eradicated by...” NCT06783478 ↗49“NK cells can persist and expand in vivo following adoptive transfer and may have a role in the treatment of late stage malignancies.” NCT03554889 ↗ “The NK cells will be collected from the donor's blood and then processed using an experimental device called a CliniMACS device.” NCT00698009 ↗ “NK cells will be intravenously infused to the patient for 2 days, with following subcutaneously injection of Interleukin-2.” NCT04209712 ↗ “Natural killer (NK) cells are one of the main type of immune cells that mediate the graft-versus-leukemia (GVL) effect.” NCT03348033 ↗ “The infusion of natural killer (NK) cells will be performed in the Infusion Center at New England Medical Center.” NCT00660166 ↗ “Haploidentical Natural Killer (NK) cells can persist and expand in vivo following adoptive transfer” NCT02845999 ↗ “Donor NK cells were purified and cultured ex vivo with IL-2 before infusion, at three dose levels.” PMID 34071607 ↗ May 2021 “Natural killer cells (NK cells) are derived from bone marrow lymphoid stem cells” NCT05143125 ↗ “All patients received both sintilimab 200mg and 3×109 NK cells every 3 weeks.” PMID 36569881 ↗ Dec 2022 “Three doses of expanded haploidentical NK cells (30-100 x 10\^6 cells /kg).” NCT05272293 ↗ “the combined therapy using cryosurgery and natural killer (NK) cells” NCT02849366 ↗ “allogeneic NK cells isolated from a HLA-haploidentical related donor” NCT00526292 ↗ |
| Known as | Nk cells, autologous | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314888 ↗ |
| Known as | SNK01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05099549 ↗ |
| Known as | Super Natural Killer Cells 01 | “SNK01 (Super Natural Killer Cells 01)” NCT04872634 ↗ |
| Action | Deplete | “They can recognize and kill abnormal cells in the body” NCT00526292 ↗ |
| Modality | Cell therapy | “autologous natural killer (NK) cells” NCT00328861 ↗ |
| Route | Intravenous | “interleukin-2 (IL-2) is given intravenously (through a small tube placed in a vein)” NCT00059475 ↗ |
| Target | TGFBR2 | “TGFBR2 KO” NCT07411599 ↗ |